Global Oncology Companion Diagnostics Market - 2025 -2033
Market Size
The global oncology companion diagnostics market size reached US$ 5.02 Billion in 2024 from US$ 4.64 Billion in 2023 and is expected to reach US$ 10.90 Billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.
Market Overview
The oncology companion diagnostics market is experiencing robust growth, driven by the rising global cancer burden, advancements in personalized medicine, and increasing regulatory approvals for targeted therapies. These diagnostics are critical for identifying patients most likely to benefit from specific cancer treatments, especially in areas like non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer. As pharmaceutical companies increasingly collaborate with diagnostic firms to co-develop drug-diagnostic pairs, the demand for companion diagnostics is expected to surge. Major market players such as Roche, Thermo Fisher Scientific, QIAGEN, and Agilent Technologies are leading innovation through next-generation sequencing (NGS), PCR, and immunohistochemistry (IHC)-based platforms.
Market Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the oncology companion diagnostics market growth
The rising global prevalence of cancer is a primary catalyst driving growth in the oncology companion diagnostics (CDx) market, as it amplifies the demand for precision diagnostics that can guide targeted treatments. For instance, according to the National Institutes of Health, by 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
As incidence rates soar, particularly for types like non-small cell lung cancer (NSCLC), breast, colorectal, and prostate cancers, there is an urgent need for more personalized and effective treatment strategies. Companion diagnostics play a critical role by identifying specific genetic mutations, biomarkers, or protein expressions that determine a patient’s likelihood to respond to a targeted therapy.
The surge in personalized medicine, combined with aging populations and lifestyle risk factors, further intensifies cancer prevalence. This trend not only increases the number of patients eligible for biomarker-driven therapies but also encourages pharmaceutical companies to co-develop diagnostic tools with therapeutics. Consequently, the market for oncology companion diagnostics is expanding rapidly, as it directly aligns with the need for safer, smarter, and more cost-effective cancer treatment pathways tailored to individual patient profiles.
Restraints:
Limited biomarker access & heterogeneity are hampering the growth of the oncology companion diagnostics market
Limited biomarker access and tumor heterogeneity significantly hamper the growth of the oncology companion diagnostics (CDx) market by reducing the effectiveness and scalability of these tests. Intra-tumor and inter-patient heterogeneity complicate diagnosis and treatment selection. A single biopsy may not accurately represent the genetic profile of the entire tumor, especially in cancers with high mutation rates or those that evolve under treatment pressure. For instance, a lung cancer patient might test negative for a biomarker in one part of the tumor but positive in another, leading to potential misclassification and suboptimal treatment.
Additionally, accessing high-quality tumor samples is a challenge in late-stage or hard-to-biopsy cancers, which can limit biomarker detection altogether. These limitations reduce the clinical reliability and utility of companion diagnostics, discouraging adoption among clinicians and slowing market expansion. As a result, the full potential of personalized oncology remains constrained by biomarker and tumor complexity.
Segment Analysis
The global oncology companion diagnostics market is segmented based on product type, technology, application, end-user, and region.
The next generation sequencing (NGS) from the technology segment is dominating the oncology companion diagnostics market with a 34.43% share in 2024
Next-generation sequencing (NGS) is dominating the oncology companion diagnostics (CDx) market due to its unparalleled ability to analyze multiple genes and biomarkers simultaneously, offering a comprehensive and efficient approach to precision oncology. Unlike traditional single-gene tests like PCR or IHC, NGS enables high-throughput, multiplexed analysis of entire cancer-related gene panels or even whole exomes, making it ideal for identifying complex mutational profiles across various tumor types.
This technological advantage is especially critical in cancers like non-small cell lung cancer (NSCLC) or melanoma, where multiple genetic alterations such as EGFR, ALK, ROS1, BRAF, and MET may guide treatment decisions. NGS panels can detect all of these mutations in one test, reducing the time and tissue required while providing actionable insights for therapies. Furthermore, NGS is essential in assessing tumor mutational burden and microsatellite instability, two emerging biomarkers critical for predicting response to immune checkpoint inhibitors like pembrolizumab.
Companies like Roche, QIAGEN, Thermo Fisher Scientific, and Illumina have developed FDA-approved NGS-based CDx platforms, which are now standard tools in advanced oncology care. For instance, in June 2025, QIAGEN N.V. and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN’s partnership with Illumina to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide.
Geographical Shares
North America is expected to dominate the global oncology companion diagnostics market with a 42.73% in 2024
North America dominates the global oncology companion diagnostics (CDx) market due to its advanced healthcare infrastructure, strong pharmaceutical and biotechnology ecosystem, and supportive regulatory environment. The United States, in particular, accounts for the largest market share, driven by the widespread adoption of precision medicine, high cancer prevalence, and substantial investment in biomarker research and targeted therapies.
The U.S. Food and Drug Administration (FDA) has played a key role by establishing clear regulatory guidelines for companion diagnostics and offering expedited pathways like Breakthrough Device Designation, which encourages innovation and rapid market entry. For instance, the FDA’s approval of FoundationOne CDx, an NGS-based test developed by Foundation Medicine (a Roche subsidiary), is now widely used for comprehensive genomic profiling in solid tumors.
Additionally, the presence of major diagnostic and life sciences companies such as Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN North America supports local production, co-development with pharma companies, and clinical trial activity. The region is also home to a large number of leading cancer centers, which routinely incorporate CDx into clinical decision-making.
Competitive Landscape
Top companies in the oncology companion diagnostics market include F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Guardant Health, Labcorp, Quest Diagnostics and Invivoscribe, Inc., among others.
The global oncology companion diagnostics market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global oncology companion diagnostics market size reached US$ 5.02 Billion in 2024 from US$ 4.64 Billion in 2023 and is expected to reach US$ 10.90 Billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.
Market Overview
The oncology companion diagnostics market is experiencing robust growth, driven by the rising global cancer burden, advancements in personalized medicine, and increasing regulatory approvals for targeted therapies. These diagnostics are critical for identifying patients most likely to benefit from specific cancer treatments, especially in areas like non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer. As pharmaceutical companies increasingly collaborate with diagnostic firms to co-develop drug-diagnostic pairs, the demand for companion diagnostics is expected to surge. Major market players such as Roche, Thermo Fisher Scientific, QIAGEN, and Agilent Technologies are leading innovation through next-generation sequencing (NGS), PCR, and immunohistochemistry (IHC)-based platforms.
Market Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the oncology companion diagnostics market growth
The rising global prevalence of cancer is a primary catalyst driving growth in the oncology companion diagnostics (CDx) market, as it amplifies the demand for precision diagnostics that can guide targeted treatments. For instance, according to the National Institutes of Health, by 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
As incidence rates soar, particularly for types like non-small cell lung cancer (NSCLC), breast, colorectal, and prostate cancers, there is an urgent need for more personalized and effective treatment strategies. Companion diagnostics play a critical role by identifying specific genetic mutations, biomarkers, or protein expressions that determine a patient’s likelihood to respond to a targeted therapy.
The surge in personalized medicine, combined with aging populations and lifestyle risk factors, further intensifies cancer prevalence. This trend not only increases the number of patients eligible for biomarker-driven therapies but also encourages pharmaceutical companies to co-develop diagnostic tools with therapeutics. Consequently, the market for oncology companion diagnostics is expanding rapidly, as it directly aligns with the need for safer, smarter, and more cost-effective cancer treatment pathways tailored to individual patient profiles.
Restraints:
Limited biomarker access & heterogeneity are hampering the growth of the oncology companion diagnostics market
Limited biomarker access and tumor heterogeneity significantly hamper the growth of the oncology companion diagnostics (CDx) market by reducing the effectiveness and scalability of these tests. Intra-tumor and inter-patient heterogeneity complicate diagnosis and treatment selection. A single biopsy may not accurately represent the genetic profile of the entire tumor, especially in cancers with high mutation rates or those that evolve under treatment pressure. For instance, a lung cancer patient might test negative for a biomarker in one part of the tumor but positive in another, leading to potential misclassification and suboptimal treatment.
Additionally, accessing high-quality tumor samples is a challenge in late-stage or hard-to-biopsy cancers, which can limit biomarker detection altogether. These limitations reduce the clinical reliability and utility of companion diagnostics, discouraging adoption among clinicians and slowing market expansion. As a result, the full potential of personalized oncology remains constrained by biomarker and tumor complexity.
Segment Analysis
The global oncology companion diagnostics market is segmented based on product type, technology, application, end-user, and region.
The next generation sequencing (NGS) from the technology segment is dominating the oncology companion diagnostics market with a 34.43% share in 2024
Next-generation sequencing (NGS) is dominating the oncology companion diagnostics (CDx) market due to its unparalleled ability to analyze multiple genes and biomarkers simultaneously, offering a comprehensive and efficient approach to precision oncology. Unlike traditional single-gene tests like PCR or IHC, NGS enables high-throughput, multiplexed analysis of entire cancer-related gene panels or even whole exomes, making it ideal for identifying complex mutational profiles across various tumor types.
This technological advantage is especially critical in cancers like non-small cell lung cancer (NSCLC) or melanoma, where multiple genetic alterations such as EGFR, ALK, ROS1, BRAF, and MET may guide treatment decisions. NGS panels can detect all of these mutations in one test, reducing the time and tissue required while providing actionable insights for therapies. Furthermore, NGS is essential in assessing tumor mutational burden and microsatellite instability, two emerging biomarkers critical for predicting response to immune checkpoint inhibitors like pembrolizumab.
Companies like Roche, QIAGEN, Thermo Fisher Scientific, and Illumina have developed FDA-approved NGS-based CDx platforms, which are now standard tools in advanced oncology care. For instance, in June 2025, QIAGEN N.V. and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN’s partnership with Illumina to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide.
Geographical Shares
North America is expected to dominate the global oncology companion diagnostics market with a 42.73% in 2024
North America dominates the global oncology companion diagnostics (CDx) market due to its advanced healthcare infrastructure, strong pharmaceutical and biotechnology ecosystem, and supportive regulatory environment. The United States, in particular, accounts for the largest market share, driven by the widespread adoption of precision medicine, high cancer prevalence, and substantial investment in biomarker research and targeted therapies.
The U.S. Food and Drug Administration (FDA) has played a key role by establishing clear regulatory guidelines for companion diagnostics and offering expedited pathways like Breakthrough Device Designation, which encourages innovation and rapid market entry. For instance, the FDA’s approval of FoundationOne CDx, an NGS-based test developed by Foundation Medicine (a Roche subsidiary), is now widely used for comprehensive genomic profiling in solid tumors.
Additionally, the presence of major diagnostic and life sciences companies such as Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN North America supports local production, co-development with pharma companies, and clinical trial activity. The region is also home to a large number of leading cancer centers, which routinely incorporate CDx into clinical decision-making.
Competitive Landscape
Top companies in the oncology companion diagnostics market include F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Guardant Health, Labcorp, Quest Diagnostics and Invivoscribe, Inc., among others.
The global oncology companion diagnostics market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer
3.1.1.2. Precision Oncology & Rise of Targeted Therapies
3.1.2. Restraints
3.1.2.1. Limited Biomarker Access & Heterogeneity
3.1.2.2. Complex Regulatory Pathways for Co-Approval
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Rise of Liquid Biopsy-Based Companion Diagnostics
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
5.4. Software
6. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Polymerase Chain Reaction (PCR)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Next Generation Sequencing (NGS)
6.4. Immunohistochemistry (IHC)
6.5. In Situ Hybridization (ISH/FISH)
6.6. Liquid Biopsy
6.7. Others
7. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Non Small Cell Lung Cancer (NSCLC)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Breast Cancer
7.4. Prostate Cancer
7.5. Colorectal Cancer
7.6. Others
8. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Laboratories
8.4. Academic and Research Institutions
8.5. Others
9. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. China
10.4.7.2. India
10.4.7.3. Japan
10.4.7.4. South Korea
10.4.7.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. Brazil
10.5.7.2. Argentina
10.5.7.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.4.4. SWOT Analysis
12.2. Agilent Technologies, Inc.
12.3. Illumina, Inc.
12.4. QIAGEN
12.5. Thermo Fisher Scientific Inc.
12.6. Myriad Genetics, Inc.
12.7. Guardant Health
12.8. Labcorp
12.9. Quest Diagnostics
12.10. Invivoscribe, Inc. (LIST NOT EXHAUSTIVE)
Assumptions and Research Methodology
1. DATA COLLECTION METHODS
2. DATA TRIANGULATION
3. FORECASTING TECHNIQUES
4. DATA VERIFICATION AND VALIDATION
5. APPENDIX
1. ABOUT US AND SERVICES
2. CONTACT US
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer
3.1.1.2. Precision Oncology & Rise of Targeted Therapies
3.1.2. Restraints
3.1.2.1. Limited Biomarker Access & Heterogeneity
3.1.2.2. Complex Regulatory Pathways for Co-Approval
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Rise of Liquid Biopsy-Based Companion Diagnostics
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
5.4. Software
6. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Polymerase Chain Reaction (PCR)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Next Generation Sequencing (NGS)
6.4. Immunohistochemistry (IHC)
6.5. In Situ Hybridization (ISH/FISH)
6.6. Liquid Biopsy
6.7. Others
7. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Non Small Cell Lung Cancer (NSCLC)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Breast Cancer
7.4. Prostate Cancer
7.5. Colorectal Cancer
7.6. Others
8. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Laboratories
8.4. Academic and Research Institutions
8.5. Others
9. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. China
10.4.7.2. India
10.4.7.3. Japan
10.4.7.4. South Korea
10.4.7.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. Brazil
10.5.7.2. Argentina
10.5.7.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.4.4. SWOT Analysis
12.2. Agilent Technologies, Inc.
12.3. Illumina, Inc.
12.4. QIAGEN
12.5. Thermo Fisher Scientific Inc.
12.6. Myriad Genetics, Inc.
12.7. Guardant Health
12.8. Labcorp
12.9. Quest Diagnostics
12.10. Invivoscribe, Inc. (LIST NOT EXHAUSTIVE)
Assumptions and Research Methodology
1. DATA COLLECTION METHODS
2. DATA TRIANGULATION
3. FORECASTING TECHNIQUES
4. DATA VERIFICATION AND VALIDATION
5. APPENDIX
1. ABOUT US AND SERVICES
2. CONTACT US
LIST OF TABLES
Table 1 Global Oncology Companion Diagnostics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Oncology Companion Diagnostics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Oncology Companion Diagnostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Oncology Companion Diagnostics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Oncology Companion Diagnostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Oncology Companion Diagnostics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Oncology Companion Diagnostics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 10 Global Oncology Companion Diagnostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Oncology Companion Diagnostics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Oncology Companion Diagnostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Oncology Companion Diagnostics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 North America Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 23 Europe Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Europe Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 33 South America Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 F. Hoffmann-La Roche Ltd: Overview
Table 42 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 43 F. Hoffmann-La Roche Ltd: Key Developments
Table 44 Agilent Technologies, Inc.: Overview
Table 45 Agilent Technologies, Inc.: Product Portfolio
Table 46 Agilent Technologies, Inc.: Key Developments
Table 47 Illumina, Inc.: Overview
Table 48 Illumina, Inc.: Product Portfolio
Table 49 Illumina, Inc.: Key Developments
Table 50 QIAGEN: Overview
Table 51 QIAGEN: Product Portfolio
Table 52 QIAGEN: Key Developments
Table 53 Thermo Fisher Scientific Inc.: Overview
Table 54 Thermo Fisher Scientific Inc.: Product Portfolio
Table 55 Thermo Fisher Scientific Inc.: Key Developments
Table 56 Myriad Genetics, Inc.: Overview
Table 57 Myriad Genetics, Inc.: Product Portfolio
Table 58 Myriad Genetics, Inc.: Key Developments
Table 59 Guardant Health: Overview
Table 60 Guardant Health: Product Portfolio
Table 61 Guardant Health: Key Developments
Table 62 Labcorp: Overview
Table 63 Labcorp: Product Portfolio
Table 64 Labcorp: Key Developments
Table 65 Quest Diagnostics: Overview
Table 66 Quest Diagnostics: Product Portfolio
Table 67 Quest Diagnostics: Key Developments
Table 68 Invivoscribe, Inc.: Overview
Table 69 Invivoscribe, Inc.: Product Portfolio
Table 70 Invivoscribe, Inc.: Key Developments
Table 1 Global Oncology Companion Diagnostics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Oncology Companion Diagnostics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Oncology Companion Diagnostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Oncology Companion Diagnostics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Oncology Companion Diagnostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Oncology Companion Diagnostics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Oncology Companion Diagnostics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 10 Global Oncology Companion Diagnostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Oncology Companion Diagnostics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Oncology Companion Diagnostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Oncology Companion Diagnostics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 North America Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 23 Europe Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Europe Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 33 South America Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Oncology Companion Diagnostics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Oncology Companion Diagnostics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Oncology Companion Diagnostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Oncology Companion Diagnostics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Oncology Companion Diagnostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 F. Hoffmann-La Roche Ltd: Overview
Table 42 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 43 F. Hoffmann-La Roche Ltd: Key Developments
Table 44 Agilent Technologies, Inc.: Overview
Table 45 Agilent Technologies, Inc.: Product Portfolio
Table 46 Agilent Technologies, Inc.: Key Developments
Table 47 Illumina, Inc.: Overview
Table 48 Illumina, Inc.: Product Portfolio
Table 49 Illumina, Inc.: Key Developments
Table 50 QIAGEN: Overview
Table 51 QIAGEN: Product Portfolio
Table 52 QIAGEN: Key Developments
Table 53 Thermo Fisher Scientific Inc.: Overview
Table 54 Thermo Fisher Scientific Inc.: Product Portfolio
Table 55 Thermo Fisher Scientific Inc.: Key Developments
Table 56 Myriad Genetics, Inc.: Overview
Table 57 Myriad Genetics, Inc.: Product Portfolio
Table 58 Myriad Genetics, Inc.: Key Developments
Table 59 Guardant Health: Overview
Table 60 Guardant Health: Product Portfolio
Table 61 Guardant Health: Key Developments
Table 62 Labcorp: Overview
Table 63 Labcorp: Product Portfolio
Table 64 Labcorp: Key Developments
Table 65 Quest Diagnostics: Overview
Table 66 Quest Diagnostics: Product Portfolio
Table 67 Quest Diagnostics: Key Developments
Table 68 Invivoscribe, Inc.: Overview
Table 69 Invivoscribe, Inc.: Product Portfolio
Table 70 Invivoscribe, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Oncology Companion Diagnostics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 10 Software Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 12 Polymerase Chain Reaction (PCR) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 13 Next Generation Sequencing (NGS) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 14 Immunohistochemistry (IHC) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 15 In Situ Hybridization (ISH/FISH) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 16 Liquid Biopsy Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 19 Non Small Cell Lung Cancer (NSCLC) Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 20 Breast Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 21 Prostate Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 22 Colorectal Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 25 Hospitals End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 26 Diagnostic Laboratories End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 27 Academic and Research Institutions End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 28 Others End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 30 North America Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 31 North America Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 32 North America Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 33 North America Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 34 North America Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 North America Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 38 Europe Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 39 Europe Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 40 Europe Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 41 Europe Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 42 Asia-Pacific Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 43 Asia-Pacific Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 45 Asia-Pacific Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 46 Asia-Pacific Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 47 Asia-Pacific Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 48 South America Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 49 South America Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 50 South America Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 51 South America Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 52 South America Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 53 South America Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 54 Middle East and Africa Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 55 Middle East and Africa Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 57 Middle East and Africa Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 58 Middle East and Africa Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 59 F. Hoffmann-La Roche Ltd: Financials
Figure 60 Agilent Technologies, Inc.: Financials
Figure 61 Illumina, Inc.: Financials
Figure 62 QIAGEN: Financials
Figure 63 Thermo Fisher Scientific Inc.: Financials
Figure 64 Myriad Genetics, Inc.: Financials
Figure 65 Guardant Health: Financials
Figure 66 Labcorp: Financials
Figure 67 Quest Diagnostics: Financials
Figure 68 Invivoscribe, Inc.: Financials
Figure 1 Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Oncology Companion Diagnostics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 10 Software Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 12 Polymerase Chain Reaction (PCR) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 13 Next Generation Sequencing (NGS) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 14 Immunohistochemistry (IHC) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 15 In Situ Hybridization (ISH/FISH) Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 16 Liquid Biopsy Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Technology in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 19 Non Small Cell Lung Cancer (NSCLC) Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 20 Breast Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 21 Prostate Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 22 Colorectal Cancer Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Application in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 25 Hospitals End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 26 Diagnostic Laboratories End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 27 Academic and Research Institutions End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 28 Others End-User in Global Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Oncology Companion Diagnostics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 30 North America Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 31 North America Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 32 North America Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 33 North America Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 34 North America Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 North America Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 38 Europe Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 39 Europe Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 40 Europe Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 41 Europe Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 42 Asia-Pacific Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 43 Asia-Pacific Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 45 Asia-Pacific Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 46 Asia-Pacific Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 47 Asia-Pacific Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 48 South America Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 49 South America Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 50 South America Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 51 South America Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 52 South America Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 53 South America Oncology Companion Diagnostics Market Share, By Country, 2024 & 2033 (%)
Figure 54 Middle East and Africa Oncology Companion Diagnostics Market Value, 2022-2033 (US$ Billion)
Figure 55 Middle East and Africa Oncology Companion Diagnostics Market Share, By Product Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Oncology Companion Diagnostics Market Share, By Technology, 2024 & 2033 (%)
Figure 57 Middle East and Africa Oncology Companion Diagnostics Market Share, By Application, 2024 & 2033 (%)
Figure 58 Middle East and Africa Oncology Companion Diagnostics Market Share, By End-User, 2024 & 2033 (%)
Figure 59 F. Hoffmann-La Roche Ltd: Financials
Figure 60 Agilent Technologies, Inc.: Financials
Figure 61 Illumina, Inc.: Financials
Figure 62 QIAGEN: Financials
Figure 63 Thermo Fisher Scientific Inc.: Financials
Figure 64 Myriad Genetics, Inc.: Financials
Figure 65 Guardant Health: Financials
Figure 66 Labcorp: Financials
Figure 67 Quest Diagnostics: Financials
Figure 68 Invivoscribe, Inc.: Financials
